Smith, Peter

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,829

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Waxman, A., Restrepo-Jaramillo, R., Thenappan, T., Ravichandran, A., Engel, P., Bajwa, A., Allen, R., Feldman, J., Argula, R., Smith, P., et al. (2021) · New England Journal of Medicine

Pulmonary Hypertension Research and TreatmentsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 666

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine

Pulmonary Hypertension Research and TreatmentsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 152

A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets

Ramachandran, S., Maarouf, A., Mitchell, K., Avades, T., Smith, P., Boulton, L., Kelly, J., Vekaria, N., & Hughes, E. (2024) · Drugs in Context

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 5